2025-10-17 - Analysis Report
Okay, here's an analysis of Procter & Gamble (PG) based on the provided data, formatted as requested.

## Procter & Gamble (PG) Analysis

Procter & Gamble Co. is a multinational consumer goods corporation focused on providing branded consumer packaged goods.

### 1. Performance vs. S&P 500 (VOO)

*   **PG Cumulative Return:** 29.80%
*   **VOO Cumulative Return:** 96.43%
*   **Disparity:** -69.0%
*   **Relative Disparity:** 0.0%

**Analysis:** PG has significantly underperformed the S&P 500 (VOO) over the specified period. The current disparity is at the lower end of its historical range, indicating a substantial performance gap.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha  | Beta  | Cap(B) |
|------------|---------|---------|--------|-------|--------|
| 2015-2017  | 21.0%   | 7.9%    | -8.0%  | 0.0   | 215.7  |
| 2016-2018  | 9.0%    | 67.3%   | -6.0%  | 0.1   | 215.8  |
| 2017-2019  | 24.0%   | 70.4%   | 2.0%   | 0.3   | 293.2  |
| 2018-2020  | 27.0%   | 78.8%   | 4.0%   | 0.4   | 326.6  |
| 2019-2021  | 41.0%   | 78.8%   | -5.0%  | 0.5   | 384.0  |
| 2020-2022  | 13.0%   | 79.4%   | 13.0%  | 0.6   | 355.8  |
| 2021-2023  | 26.0%   | 79.4%   | 24.0%  | 0.4   | 344.0  |
| 2022-2024  | 9.0%    | 79.4%   | -12.0% | 0.4   | 393.5  |
| 2023-2025  | -14.0%  | 80.1%   | -75.0% | 0.2   | 350.1  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Fluctuates significantly over the years, ranging from -14.0% to 41.0%.
*   **MDD (Maximum Drawdown):**  High MDD values suggest periods of significant losses.
*   **Alpha:**  Shows periods of both outperformance (positive Alpha) and underperformance (negative Alpha) relative to the market.  The most recent period shows a very significant underperformance.
*   **Beta:** Generally low, indicating PG's price is less volatile than the market.
*   **Cap(B):**  Market capitalization in billions.

### 2. Recent Stock Price Movement

*   **Current Price:** 149.16
*   **Last Market Data:** Price: 149.6, Previous Close: 147.42, Change: 1.48
*   **5-day Moving Average:** 149.31
*   **20-day Moving Average:** 152.54
*   **60-day Moving Average:** 155.03

**Analysis:**

*   The recent market data indicates a slight positive change.
*   The stock price is trading below its 5-day, 20-day, and 60-day moving averages, suggesting a potential short-term downtrend.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 39.23 (Approaching oversold territory)
*   **PPO:** -0.258
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (7 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-09-02)
*   **Recent (20-day) Relative Disparity Change:** 0.0 (-) (Short-term decrease)
*   **Expected Return (%):** 284.8 (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI is approaching oversold levels, potentially indicating a buying opportunity.
*   The PPO being negative may imply a downtrend.
*   The hybrid signal suggest to buy.
*   The high expected return, if accurate, suggests significant potential outperformance in the long term (2+ years) through dollar-cost averaging.

### 4. Recent News & Significant Events

*   **Product Launches & Marketing Campaigns:** Charmin roll size increase, Herbal Essences "Scent Traps" campaign, Prilosec OTC partnership with Cedric The Entertainer, Head & Shoulders NFL campaign.
*   **Dividend Announcement:** P&G Declares Quarterly Dividend.

**Impact:**

*   The news indicates a focus on product innovation, marketing, and shareholder returns through dividends. These events are generally positive for the company's brand image and investor confidence.

**4-2) Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 2.04 (~Buy)
*   **Target Price (avg/high/low):** 169.09 / 186.00 / 147.00

**Analysis:**  Analysts generally have a positive outlook on the stock, with a "Buy" consensus and a target price above the current market price.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-04-24 | 1.58  | 19.78 B$   |
| 2025-01-22 | 1.94  | 21.88 B$   |
| 2024-10-18 | 1.65  | 21.74 B$   |
| 2024-04-19 | 1.56  | 20.20 B$   |
| 2025-04-24 | 1.56  | 20.20 B$   |

**Analysis:**

*   Earnings Per Share (EPS) has fluctuated, with the highest EPS in 2025-01-22 and the lowest in 2024-04-19 & 2025-04-24.
*   Revenue has also fluctuated.

### 6. Financial Information

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $20.89B   | 49.11%        |
| 2025-03-31 | $19.78B   | 50.98%        |
| 2024-12-31 | $21.88B   | 52.39%        |
| 2024-09-30 | $21.74B   | 52.06%        |
| 2024-06-30 | $20.53B   | 49.60%        |

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-06-30 | $52.01B   | 6.95%   |
| 2025-03-31 | $52.27B   | 7.21%   |
| 2024-12-31 | $51.17B   | 9.05%   |
| 2024-09-30 | $51.84B   | 7.64%   |
| 2024-06-30 | $50.29B   | 6.24%   |

**Analysis:**

*   **Revenue:**  Revenue has shown some fluctuation, with a recent dip.
*   **Profit Margin:** Profit margins are strong, generally above 49%, but have recently declined.
*   **Equity:** Equity has remained relatively stable.
*   **ROE (Return on Equity):** ROE has fluctuated, showing a recent decline, suggesting decreased profitability relative to equity.

### 7. Overall Assessment

**Summary:**

PG has underperformed the S&P 500 significantly. Recent price action suggests a short-term downtrend, but the RSI is approaching oversold levels. Analyst consensus is positive, and the company continues to focus on product innovation and shareholder returns. While revenue and profitability remain strong, recent declines in profit margin and ROE are areas to monitor.

**Considerations:**

*   **Underperformance:** The underperformance relative to the S&P 500 is a significant concern.
*   **Technical Indicators:**  The approaching oversold RSI could present a potential buying opportunity for long-term investors, especially given the analyst target price.
*   **Financial Health:**  P&G remains a financially strong company with solid revenue and profit margins, although recent trends warrant attention.
*   **News & Events:** Recent news surrounding product launches and dividends should be viewed positively,

**Recommendation (Disclaimer: This is not financial advice):**

Given the underperformance, the investor should carefully consider their investment goals and risk tolerance. While PG is a stable company with a strong dividend, the lack of growth compared to the broader market is a valid concern. Dollar-cost averaging may be appropriate.
